You are here: Industry Insights > DLBCL

News List

ADC Therapeutics, SOPHiA GENETICS Partner for Biomarker Discovery contractpharma
August 08, 2019
Pivotal Phase II trial to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) in DLBCL.
Five-Year Survival Less Than 40 Percent in Seniors With DLBCL drugs
July 01, 2019
Five-Year Survival Less Than 40 Percent in Seniors With DLBCL.
Polivy Chemoimmunotherapy Regimen Approved to Treat DLBCL drugs
June 12, 2019
Polivy Chemoimmunotherapy Regimen Approved to Treat DLBCL.
Chemoimmunotherapy Regimen Approved to Treat DLBCL drugs
June 11, 2019
Chemoimmunotherapy Regimen Approved to Treat DLBCL.
Novartis unveils strong longer-term Kymriah data at ASH 2018 pharmafile
December 04, 2018
Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of Hematology (ASH) Annual Meeting 2018, showing that the treatment demonstrated
Global 2-year trial reports on CAR-T therapy to treat DLBCL europeanpharmaceuticalreview
December 04, 2018
A study has reported results of a clinical trial using CAR-T therapy where over half of the cancer patients were alive two year after the start…
Forty Seven’s anti-CD47 combo shows promise in non-Hodgkin lymphoma fiercebiotech
November 02, 2018
An immunotherapy combining Roche’s blood cancer drug Rituxan and an anti-CD47 drug developed at Stanford University shrank the cancers of half the patients in a small phase 1 trial.
CAR-T therapies leap towards EU approval pharmatimes
July 03, 2018
The stage has been set for approval of the first chimeric antigen T-cell therapies (CAR-T) in Europe, after Novartis’ Kymriah and Gilead’s Yescarta both won backing from the Committee for Medicinal Products for Human Use (CHMP).
German Biotech MorphoSys Seeks Nasdaq Listing biospace
March 26, 2018
MorphoSys, a Germany-based biopharmaceutical company, is aiming for a listing on the Nasdaq exchange.

Previous page 1 2 Next page